Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Shares Outstanding: 2011-2025

Historic Shares Outstanding for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $52.4 million.

  • Abeona Therapeutics' Shares Outstanding rose 20.73% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year increase of 20.73%. This contributed to the annual value of $45.6 million for FY2024, which is 72.09% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Shares Outstanding stood at $52.4 million, which was up 2.25% from $51.2 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Shares Outstanding ranged from a high of $52.4 million in Q3 2025 and a low of $4.0 million during Q1 2021.
  • Over the past 3 years, Abeona Therapeutics' median Shares Outstanding value was $41.7 million (recorded in 2024), while the average stood at $36.5 million.
  • In the last 5 years, Abeona Therapeutics' Shares Outstanding tumbled by 95.26% in 2021 and then soared by 265.87% in 2023.
  • Abeona Therapeutics' Shares Outstanding (Quarterly) stood at $5.9 million in 2021, then skyrocketed by 200.94% to $17.7 million in 2022, then skyrocketed by 49.69% to $26.5 million in 2023, then spiked by 72.09% to $45.6 million in 2024, then climbed by 20.73% to $52.4 million in 2025.
  • Its Shares Outstanding was $52.4 million in Q3 2025, compared to $51.2 million in Q2 2025 and $49.0 million in Q1 2025.